Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510931 | 0.85 | DRD2 (0.60) | DRD2 | |
| SCHEMBL26306413 | 0.84 | DRD2 (0.58) | DRD2SIGMAR1CARM1PRMT6DRD3 | |
| SCHEMBL6200348 | 0.84 | ADRA1A (0.62) | DRD2ADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL25378584 | 0.83 | DRD2 (0.49) | DRD2SIGMAR1DRD3 | |
| SCHEMBL31252147 | 0.83 | DRD2 (0.49) | DRD2SIGMAR1DRD3 | |
| SCHEMBL6848549 | 0.83 | CCR2 (0.50) | DRD2ADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL6848950 | 0.83 | DRD2 (0.55) | DRD2SIGMAR1DRD3 | |
| SCHEMBL7662199 | 0.83 | DRD2 (0.54) | DRD2ADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL13555688 | 0.82 | ADRA1D (0.47) | DRD2ADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL12501782 | 0.81 | DRD2 (0.65) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | DRD2 119/4885ADRA1D 48/4885ADRA1A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.